Hicks R C, Ellis M, Mir-Hasseine R, Higman D J, Nott D, Greenhalgh R M, Powell J T
Department of Surgery, Charing Cross & Westminster Medical School, London, U.K.
Eur J Vasc Endovasc Surg. 1995 May;9(4):415-20. doi: 10.1016/s1078-5884(05)80009-7.
The aim of this study was to identify factors associated with the development of graft stenoses in the first year after bypass.
Between January 1992 and April 1993, 75 consecutive patients undergoing distal vein bypass surgery were entered into a graft surveillance programme at Charing Cross Hospital. The grafts (n = 79) were surveyed by colour flow Doppler ultrasonography at 7 days, 3, 6, 9 and 12 months and the site of stenoses (> 50%) recorded. Position of the distal anastomosis, graft type (in situ or reverse) and clinical history were recorded. At the 3-month surveillance a blood sample was taken for the estimation of smoking markers, lipids and fibrinogen.
The site of the distal anastomosis was to the suprageniculate popliteal in nine, infrageniculate popliteal in 32 and tibio/peroneal vessels in 38 cases. In the first month following bypass there were six deaths, giving a 30 day mortality of 7.5%, three patients were lost to follow up, seven grafts occluded, three were replaced by PTFE, four patients underwent amputation and one patient had a redo vein graft. In the remaining grafts 20/63 (32%) developed stenoses within the first year after bypass. The development of a graft stenosis was not associated with sex, diabetic status, site of distal anastomosis, graft type or serum lipids. Multiple regression analysis identified only one factor associated significantly with the development of vein graft stenosis: fibrinogen concentration (p = 0.003). Life table analysis showed that after 1 year only 46% of grafts remained free of stenoses in patients with above median fibrinogen concentrations compared with 84% of grafts in patients with below median fibrinogen concentrations, p = 0.009.
Increased plasma fibrinogen concentration is a potent risk factor for the development of vein graft stenosis. These results prompt consideration of the role of fibrinogen in stimulating smooth muscle cell proliferation in the stenotic lesion.
本研究旨在确定与搭桥术后第一年移植物狭窄发生相关的因素。
1992年1月至1993年4月期间,75例连续接受远端静脉搭桥手术的患者进入查令十字医院的移植物监测项目。对79个移植物在术后7天、3、6、9和12个月进行彩色多普勒超声检查,并记录狭窄部位(狭窄>50%)。记录远端吻合口位置、移植物类型(原位或逆转)及临床病史。在3个月监测时采集血样以评估吸烟标志物、血脂和纤维蛋白原。
远端吻合口位置在膝上腘静脉的有9例,膝下腘静脉的有32例,胫/腓血管的有38例。搭桥术后第一个月有6例死亡,30天死亡率为7.5%,3例患者失访,7个移植物闭塞,3个被聚四氟乙烯移植物替代,4例患者接受截肢,1例患者进行了再次静脉搭桥。在其余移植物中,20/63(32%)在搭桥术后第一年内出现狭窄。移植物狭窄的发生与性别、糖尿病状态、远端吻合口位置、移植物类型或血脂无关。多元回归分析仅确定了一个与静脉移植物狭窄发生显著相关的因素:纤维蛋白原浓度(p = 0.003)。生存分析表明,1年后纤维蛋白原浓度高于中位数的患者中只有46%的移植物无狭窄,而纤维蛋白原浓度低于中位数的患者中这一比例为84%,p = 0.009。
血浆纤维蛋白原浓度升高是静脉移植物狭窄发生的一个重要危险因素。这些结果促使人们考虑纤维蛋白原在刺激狭窄病变中平滑肌细胞增殖方面的作用。